There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs). This study aimed to evaluate two different NA combination therapies in patients with suboptimal response to adefovir (ADV).
Methods
In this study, 72 CHB patients with suboptimal response to ADV were assessed, with 37 patients receiving lamivudine plus ADV (group A) and 35 patients receiving telbivudine plus ADV (group B).
Results
Baseline characteristics between two groups were similar. At month 12, rates of biochemical response (BR) and virological response (VR) were similar between groups A and B (17/19 versus 18/20 for BR, [P=0.269] and 30/37 versus 31/35 for VR [P=0.377]), and cumulative rates of serological response were greater in group B than in group A (10/26 versus 2/28 in hepatitis B e antigen [HBeAg] loss [P=0.006] and 7/26 versus 1/28 in HBeAg/ hepatitis B e antibody seroconversion [P=0.022]). After 12-month treatment, 8.1% (3/37) of patients in group A and 5.7% (2/35) of patients in group B had VR; among patients in group A, two had rtM204V/I and rtL180M and one had rtN236T, whereas the two patients in group B had rtM204I+rtL180M.
Conclusions
Both combination therapies led to a significant decrease in HBV DNA. HBeAg serological outcomes were higher with telbivudine plus ADV combination therapy.
References
1.
WilliamsR.Global challenges in liver disease. Hepatology2006; 44: 521–526.
2.
European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. J Hepatol2009; 50: 227–242.
JiaJ.D., YaoG.B.Achieving ultimate control of hepatitis B infection in China: progress and challenges. J Viral Hepat2010; 17Suppl 1: 2–3.
5.
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Gan Zang Bing Za Zhi2011; 19: 13–24. Chinese.
6.
LiawY.F., LeungN., KaoJ.H.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int2008; 2: 263–283.
7.
PapatheodoridisG.V., DimouE., PapadimitropoulosV.Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol2002; 97: 1618–1628.
8.
CroaghC.M., BellS.J., LocarniniS., DesmondP.V.Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing. Intern Med J2012; 42: 170–175.
9.
LocarniniS.Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int2008; 2: 147–151.
10.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology2009; 137: 1593–1608.
11.
LocarniniS.Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management. J Gastroenterol Hepatol2010; 25: 649–651.
12.
LamperticoP.Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B: from guidelines to field practice. J Hepatol2009; 50: 644–647.
13.
Carrouée-DurantelS., DurantelD., Werle-LapostolleB.Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther2008; 13: 381–388.
14.
GallegoA., SheldonJ., Garcia-SamaniegoJ.Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat2008; 15: 392–398.
15.
MarcellinP., HeathcoteE.J., ButiM.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med2008; 359: 2442–2455.
16.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology2006; 131: 1743–1751.
17.
KeeffeE.B., ZeuzemS., KoffR.S.Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol2007; 5: 890–897.
18.
LaiC.L., GaneE., LiawY.F.Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med2007; 357: 2576–2588.
19.
LiawY.F., GaneE., LeungN.2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology2009; 136: 486–495.
ReijndersJ.G., PasS.D., SchuttenM., de ManR.A., JanssenH.L.Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol2009; 50: 674–683.
22.
GhanyM.G., DooE.C.Antiviral resistance and hepatitis B therapy. Hepatology2009; 49Suppl 5: S174–S184.
23.
LocarniniS.Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis2005; 25Suppl 1: 9–19.
24.
BrunettoM.R., LokA.S.New approaches to optimize treatment responses in chronic hepatitis B. Antivir Ther2010; 15Suppl 3: 61–68.
25.
WangL.C., ChenE.Q., CaoJ.Combination of lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. J Viral Hepat2010; 17: 178–184.
26.
ChenE.Q., ZhouT.Y., TangH.Combination of telbivudine and adefovir dipivoxil therapy in chronic hepatitis B patients with poor response to adefovir dipivoxil monotherapy. Int J Infect Dis2010; 14Suppl 2: S18.
27.
ChenE.Q., WangL.C., LeiJ., XuL., TangH.Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J2009; 6: 163.
28.
ShengY.J., LiuJ.Y., TongS.W.Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J2011; 8: 393.
29.
AlcantaraF.F., TangH., McLachlanA.Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. Nucleic Acids Res2002; 30: 2068–2075.
30.
WestlandC.E., YangH., DelaneyW.E.4th. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat2005; 12: 67–73.
31.
WongC.R., TrinhH.N., YipB.High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin Gastroenterol2011; 45: 900–905.
32.
LiawY.F.HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int2009; doi: 10.1007/s12072-009-9140-3.
33.
McKeageK., KeamS.J.Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs2010; 70: 1857–1883.
34.
HartwellD., JonesJ., HarrisP., CooperK.Telbivudine for the treatment of chronic hepatitis B infection. Health Technol Assess2009; 13Suppl 3: 23–30.
35.
ButD.Y., YuenM.F., FungJ., LaiC.L.Safety evaluation of telbivudine. Expert Opin Drug Saf2010; 9: 821–829.
